Studying administration of sodium bicarbonate and magnesium sulfate in clinical betterment of acute organophosphorous pesticide poisoning.

Comparing therapeutic effects of sodium bicarbonate with magnesium sulfate in moderate and severe acute organophosphorous pesticide poisoning.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138803031187N2

Enrollment

120

Registered

2014-12-17

Start date

2008-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate and severe acute Organophosphorous pesticide poisoning. Organophosphorous and Carbamate insecticides

Interventions

Intervention 1: ?First intervention group: Intravenous infusion of 6 to 12 Sodium Bicarbonate (Pasteur Institute) 7.5% 50 ML Bags in every 24 hours for the first 3 days of hospitalization, aiming at a

Treatment - Drugs

?First intervention group: Intravenous infusion of 6 to 12 Sodium Bicarbonate (Pasteur Institute) 7.5% 50 ML Bags in every 24 hours for the first 3 days of hospitalization, aiming at arterial pH betw

Second intervention group: Intravenous infusion of Magnesium Sulfate (Samen Corporation) 20% 10 ML Vial, 4 grams in 4 hours, in the very beginning of admission.

Third intervention group: Intravenous infusion of 6 to 12 Sodium Bicarbonate (Pasteur Institute) 7.5% 50 ML Bags in every 24 hours for the first 3 days of hospitalization, aiming at arterial pH betwe

Control (forth) group: Merely the conventional treatment. No supplementary treatment.

Eligibility

Sex/Gender

All

Age

14 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients aged 14 to 65 years old with moderate and severe acute organophosphorous pesticide poisoning referring to Imam Reza Hospital, Mashhad, Iran who or whose guardian has confirmed the relevant informed consent. Exclusion criteria: Any evidence of conductive heart diseases and myocardial injuries (inspected by Electrocardiography and plasma Troponin, every 12 hours respectively); renal dysfunction (less than 100 ML urine output for every 4 hours); concurrent administration of Digitals or Central Nervous System suppressors or Neuromuscular Junction blockers (through patients' drug history); any manifestation of magnesium intoxication (through physical examination every 2 hours while administrating magnesium sulfate).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The dosage of Atropine administered for patients' Atropinization. Timepoint: In the first day of admission. Method of measurement: In scale of milligrams and according to the notes of patients' dossiers.;Hospitalization duration. Timepoint: At the end of hospitalization. Method of measurement: In scale of days and according to the notes of patients' dossiers.;Necessity to the Intensive Care Unit. Timepoint: Every morning and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Necessity to mechanical ventilation. Timepoint: Every morning and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Necessity to administrating Benzodiazepines. Timepoint: Every 12 hours and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Seizure incidence. Timepoint: Every day and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Patients' outcome. Timepoint: At the end of hospitalization. Method of measurement: According to the notes of patients' dossiers, based on whether discharged with no organophosphorous poisoning complications, discharged with some organophosphorous poisoning complications and death.	—

Measure

Time frame

The dosage of Atropine administered for patients' Atropinization. Timepoint: In the first day of admission. Method of measurement: In scale of milligrams and according to the notes of patients' dossiers.;Hospitalization duration. Timepoint: At the end of hospitalization. Method of measurement: In scale of days and according to the notes of patients' dossiers.;Necessity to the Intensive Care Unit. Timepoint: Every morning and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Necessity to mechanical ventilation. Timepoint: Every morning and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Necessity to administrating Benzodiazepines. Timepoint: Every 12 hours and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Seizure incidence. Timepoint: Every day and at the end of hospitalization. Method of measurement: According to the notes of patients' dossiers.;Patients' outcome. Timepoint: At the end of hospitalization. Method of measurement: According to the notes of patients' dossiers, based on whether discharged with no organophosphorous poisoning complications, discharged with some organophosphorous poisoning complications and death.

—

Secondary

Measure	Time frame
Arterial blood pH. Timepoint: Every 12 hours. Method of measurement: Arterial blood pH measurement by pH meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza afshari, M.D.

Medical Toxicology Center and Addiction Research Center, Mashhad University of Medical Sciences

afsharir@mums.ac.ir+98 51 3859 8973

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026